etoposide has been researched along with Canine Diseases in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boyé, P; Floch, F; Fournel-Fleury, C; Serres, F; Tierny, D | 1 |
| Bouchaert, E; Boyé, P; Gomes, B; Hordeaux, J; Marescaux, L; Serres, F; Tierny, D | 1 |
| Choisunirachon, N; Kok, MK; Nakagawa, T; Nishimura, R; Ong, SM; Saeki, K; Tanaka, Y; Yoshitake, R | 1 |
| Nakagawa, T; Nishimura, R; Ong, SM; Saeki, K; Tanaka, Y; Yamamoto, H; Yoshitake, R | 1 |
| Kok, MK; Nakagawa, T; Nishimura, R; Ong, SM; Saeki, K | 1 |
| Asada, H; Fujino, Y; Goto-Koshino, Y; Ohno, K; Tomiyasu, H; Tsujimoto, H | 1 |
| Blazejczyk, A; Dziegiel, P; Dzimira, S; Hildebrand, W; Krupa, A; Kutkowska, J; Obminska-Mrukowicz, B; Pawlak, A; Rapak, A; Strzadala, L; Wietrzyk, J; Ziolo, E | 1 |
| Nakagawa, T; Nishimura, R; Ong, SM; Saeki, K; Tanaka, Y | 1 |
| Autio, K; Balkman, CE; Beaulieu, BB; Flory, AB; Kiselow, MA; Lewis, LD; Rassnick, KM | 1 |
| Cockburn, CA; Ogilvie, GK; Reschke, RW; Tranquilli, WJ; Weigel, RM | 1 |
1 trial(s) available for etoposide and Canine Diseases
| Article | Year |
|---|---|
Prognostic value of pretreatment plasma D-dimer level in dogs with intermediate to high-grade non-Hodgkin lymphoma.
Topics: Animals; Antineoplastic Agents; Dog Diseases; Dogs; Double-Blind Method; Etoposide; Female; Fibrin Fibrinogen Degradation Products; Lymphoma, Non-Hodgkin; Male; Organophosphorus Compounds; Podophyllotoxin; Prognosis; Thymidine Kinase | 2021 |
9 other study(ies) available for etoposide and Canine Diseases
| Article | Year |
|---|---|
Dose escalation study to evaluate safety, tolerability and efficacy of intravenous etoposide phosphate administration in 27 dogs with multicentric lymphoma.
Topics: Administration, Intravenous; Animals; Antineoplastic Agents; Dog Diseases; Dogs; Etoposide; Lymphoma; Neoplasm Grading; Neoplasm Staging; Organophosphorus Compounds; Treatment Outcome; Tumor Burden | 2017 |
Anti-tumour efficacy of etoposide alone and in combination with piroxicam against canine osteosarcoma in a xenograft model.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Phytogenic; Dog Diseases; Dogs; Etoposide; Heterografts; Mice; Mice, Inbred BALB C; Osteosarcoma; Piroxicam | 2017 |
Anti-neoplastic effects of topoisomerase inhibitors in canine mammary carcinoma, melanoma, and osteosarcoma cell lines.
Topics: Animals; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Dog Diseases; Dogs; Etoposide; Female; Mammary Neoplasms, Animal; Melanoma; Mice; Neoplasms, Experimental; Osteosarcoma; Topoisomerase Inhibitors | 2017 |
YM155 enhances the cytotoxic activity of etoposide against canine osteosarcoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Cell Proliferation; Dog Diseases; Dogs; Drug Synergism; Etoposide; Humans; Imidazoles; Mice; Naphthoquinones; Osteosarcoma; Survivin; Xenograft Model Antitumor Assays | 2019 |
Evaluation of the drug sensitivity and expression of 16 drug resistance-related genes in canine histiocytic sarcoma cell lines.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytarabine; Dog Diseases; Dogs; Doxorubicin; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Histiocytic Sarcoma; Melphalan; Methotrexate; Nimustine; Paclitaxel; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Vinblastine; Vincristine | 2015 |
A novel canine B-cell leukaemia cell line. Establishment, characterisation and sensitivity to chemotherapeutics.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Celecoxib; Cell Line, Tumor; Dexamethasone; Dog Diseases; Dogs; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Imatinib Mesylate; Leukemia, B-Cell; Mice; Neoplasm Transplantation; Piroxicam | 2017 |
Effects of etoposide alone and in combination with piroxicam on canine osteosarcoma cell lines.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Phytogenic; Apoptosis; Bone Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dog Diseases; Dogs; Down-Regulation; Etoposide; Osteosarcoma; Piroxicam; Up-Regulation | 2016 |
Oral bioavailability of etoposide after administration of a single dose to tumor-bearing dogs.
Topics: Administration, Oral; Animals; Area Under Curve; Biological Availability; Cross-Over Studies; Dog Diseases; Dogs; Etoposide; Infusions, Intravenous; Kinetics; Neoplasms | 2008 |
Hypotension and cutaneous reactions associated with intravenous administration of etoposide in the dog.
Topics: Animals; Blood Pressure; Blood Pressure Determination; Dog Diseases; Dogs; Drug Eruptions; Etoposide; Hypotension; Injections, Intravenous; Male | 1988 |